Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: Radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen

Journal of Nuclear Medicine

Volumn 46, Issue 5, 2005, Pages 850-858

  Vallabhajosula, Shankar ^a,b   Goldsmith, Stanley J ^a   Hamacher, Klaus A ^a   Kostakoglu, Lale ^a   Konishi, Shota ^a   Milowski, Mathew I ^a   Nanus, David M ^a   Bander, Neil H ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

177Lu labeled J591 monoclonal antibody; Myelotoxicity; Radioimmunotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; INDIUM 111; LUTETIUM 177; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRACER; YTTRIUM 90; LUTETIUM; MONOCLONAL ANTIBODY J591; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; YTTRIUM;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOSIMETRY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SCREENING; GRANULOCYTE; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RADIOIMMUNOTHERAPY; SCINTISCANNING; THROMBOCYTE COUNT; THROMBOCYTOPENIA; ANTIBODY SPECIFICITY; BODY BURDEN; BONE MARROW; BONE MARROW DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; IMMUNOLOGY; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PROSTATE TUMOR; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIATION RESPONSE; RELATIVE BIOLOGIC EFFECTIVENESS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BODY BURDEN; BONE MARROW; BONE MARROW DISEASES; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LUTETIUM; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGAN SPECIFICITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; YTTRIUM RADIOISOTOPES;

EID: 20644436713     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. DeNardo GL, Siantar CLH, DeNardo SJ. Radiation dosimetry for radionuclide therapy in a non-myeloablative strategy. Cancer Biother Radiopharm. 2002;17:107-118.
2. Behr TM, Stabin MG, Behe M, et al. Studies on the radiation dosimetry in radioimmunotherapy an experimental investigation of factors influencing the radiation induced myelotoxicity in therapy with β-, Auger/conversion election-, or α-emitters. Clin Cancer Res. 1999;5:3031s-3043s.
3. Aksentijevich I, Flinn I. Chemotherapy and bone marrow reserve: lessons learned from autologous stem cell transplantation. Cancer Biother Radiopharm. 2002; 17:399-403.
4. Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Nucl Med Biol. 1989;16:553-559.
5. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
6. Sgouros G, Jureidini IM, Scott AM, Graham MC, Larson SM, Scheinberg DA. Bone marrow dosimetry: regional variability of marrow-localizing antibody. J Nucl Med. 1996;7:695-698.
7. Zanzonico P, Sgouros G. Predicting myelotoxicity in radioimmunotherapy: what does dosimetry contribute? J Nucl Med. 1997;11:1753-1754.
8. Lim S-M, Denardo GL, DeNardo DA, et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med. 1997;38:1374-1378.
9. Sgouros G, Stabin M, Erdi Y, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys. 2000;27: 2150-2164.
10. 131I-CC49 radioimmunotherapy in three phase II clinical trials. Cancer Biother Radiopharm. 1997;12:79-87.
11. 131I-labeled anti-carcinoembryonic antigen monoclonal antibodies. J Nucl Med. 1999; 40:1609-1616.
12. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27:766-777.
13. DeNardo DA, DeNardo GL, O'Donnell RT, et al. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer. 1997;80(suppl):2558-2566.
14. 90Y-antibody therapy. J Nucl Med. 2002;43:1245-1253.
15. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170:1717-1721.
16. 90Y-labeled anti-prostate specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22:2522-2531.
17. 177Lu labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. In press.
18. 177Lu? J Nucl Med. 2005;46:634-641.
19. 177Lu labeled J591 monoclonal antibody: prediction of myelotoxicity [abstract]. J Nucl Med. 2004;45(suppl):348P.
20. Smith Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. Cancer Res. 2000;60:5237-5243.
21. Zanzonico PB. Internal radionuclide radiation dosimetry: a review of basic concepts and recent developments. J Nucl Med. 2000;41:297-308.
22. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
23. Clairand I, Ricard M, Gouriou J, Paola MD, Aubert B. DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. J Nucl Med. 1999;40:1517-1523.
24. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharm. 1990; 3:213-233.
25. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun. 1993;14:587-595.
26. Macey DJ, DeNardo SJ, DeNardo GL, DeNardo DA, Shen S. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med. 1995;20:117-125.
27. Juweid M, Sharkey RM, Siegel JA, Behr T, Goldenberg DM. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake. Cancer Res. 1995; 55(suppl):5827-5831.
28. Lim S, DeNardo GL, DeNardo DA, O'Donnell RT, Yuan A, DeNardo SJ. Prediction of myelotoxicity using semi-quantitative marrow image scores. J Nucl Med. 1997;38:1749-1753.
29. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm. 2002;17:445-464.
30. Stabin MG, Siegel JA, Sparks RB, Eckerman KF, Breitz HB. Contribution to red marrow absorbed dose from total body activity: a collection to the MIRD method. J Nucl Med. 2001;42:492-498.